UK's IP Group HY26 NAV/share rises on Pfizer obesity programme progress
UK's IP Group HY26 NAV/share rises on Pfizer obesity programme progress
Overview
UK science and tech investor's HY26 NAV/share grew 3.2%, driven by Pfizer obesity asset progress
Company reported HY26 profit of £31.2 mln, reversing prior-year loss
Cash proceeds from exits in HY26 reached £68.7 mln, surpassing FY25 total
Outlook
IP Group targets more than £250m of exits by end-2027
Company expects value-driving milestones across portfolio over next 18 months
Company sees supportive environment for science and technology investments
Result Drivers
PFIZER OBESITY ASSET - £27m uplift in Pfizer Obesity Royalty Income asset valuation following positive clinical progress and reduced development risk
EXIT PROCEEDS - Cash proceeds from exits reached £68.7m, with major contributions from Monolith, Hinge Health, and Centessa exits
PORTFOLIO FUNDRAISING - Portfolio companies raised £543m from third parties, which the company says validates portfolio quality
Company press release: ID:nRSO7151Ua
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Net Income |
| GBP 31.20 mln |
|
H1 Net Asset Value |
| GBP 1.006 bln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the investment management & fund operators peer group is "buy"
Wall Street's median 12-month price target for IP Group PLC is GBp114.50, about 74.3% above its September 14 closing price of GBp65.70
The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 6 three months ago
Reuters Recommended Reads
Sept 14 - Vista Equity exploring strategic options for financial software provider Finastra, sources say
Sept 14 - China's DeepSeek hires dealmaker as CFO ahead of possible IPO
Sept 14 - JPMorgan to launch long-awaited 'frontier' local currency debt index
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)